FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561235181> ?p ?o ?g. }

• W2561235181 endingPage "9365" @default.
• W2561235181 startingPage "9354" @default.
• W2561235181 abstract "// Yu Wang 1, 2, 3, 4, * , Jiacheng Lin 3, 4, * , Jiujie Cui 2, 3, 4, * , Ting Han 1, 2, 3, 4 , Feng Jiao 2, 3, 4 , Zhuo Meng 1, 2, 3, 4 , Liwei Wang 1, 2, 3, 4 1 Department of Medical Oncology and Pancreatic Cancer Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200000, China 2 Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201620, China 3 Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China 4 State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China * These authors are contributed equally to this work Correspondence to: Liwei Wang, email: liweiwang@shsmu.edu.cn Keywords: PD-1/PD-L1, mismatch repair enzymes, pancreatic cancer, prognosis Received: September 27, 2016      Accepted: December 16, 2016      Published: December 21, 2016 ABSTRACT Pancreatic cancer (PC) is a highly lethal cancer. Thus, the immune molecular markers which help to select PC patients are especially important. In this study, we aimed at systematically analyzing the expression of MLH1, MSH2, PD-L1 and PD-1, investigate their clinical significance and prognostic value. We found that high expression of PD-L1 on cancer cell membranes correlated with lymph node metastasis ( P = 0.033) and strongly correlated with poor-differentiation ( P = 0.008); high expression of PD-1 on cell membranes of T-cells correlated with well-differentiation ( P = 0.018) and strongly correlated with advanced T stage ( P = 0.004); high PD-1 expression was associated with a significantly superior OS and was an independent prognostic factor ( P = 0.031). Then we found an inverse correlation between MSH2 expression and PD-L1 expression (Spearman correlation coefficient r = −0.295, P = 0.004). In subgroup analyses, we observed that PD-1 expression level was associated with OS only at low PD-L1 expression subgroup ( P = 0.021). Finally, when we stratified the cases into four subgroups based on PD-1 expression and stroma density, we found that patients with high PD-1 expression and dense stroma had a better OS, while patients with low PD-1 expression and moderate stroma showed a worst outcome. Our result may provide more effective molecular markers for immunotherapeutic strategies of PC patients in clinical practice." @default.
• W2561235181 created "2017-01-06" @default.
• W2561235181 creator A5000441787 @default.
• W2561235181 creator A5036246350 @default.
• W2561235181 creator A5047704890 @default.
• W2561235181 creator A5055723755 @default.
• W2561235181 creator A5079594267 @default.
• W2561235181 creator A5081109406 @default.
• W2561235181 creator A5088195735 @default.
• W2561235181 date "2016-12-21" @default.
• W2561235181 modified "2023-09-28" @default.
• W2561235181 title "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer" @default.
• W2561235181 cites W1940241680 @default.
• W2561235181 cites W1946441967 @default.
• W2561235181 cites W1971208896 @default.
• W2561235181 cites W1977381583 @default.
• W2561235181 cites W2022334439 @default.
• W2561235181 cites W2046038516 @default.
• W2561235181 cites W2070026322 @default.
• W2561235181 cites W2071462987 @default.
• W2561235181 cites W2071606440 @default.
• W2561235181 cites W2075819066 @default.
• W2561235181 cites W2097755600 @default.
• W2561235181 cites W2101653483 @default.
• W2561235181 cites W2106511606 @default.
• W2561235181 cites W2109485845 @default.
• W2561235181 cites W2112474929 @default.
• W2561235181 cites W2125150261 @default.
• W2561235181 cites W2143163879 @default.
• W2561235181 cites W2143772132 @default.
• W2561235181 cites W2148300747 @default.
• W2561235181 cites W2160834915 @default.
• W2561235181 cites W2207381945 @default.
• W2561235181 cites W2261461400 @default.
• W2561235181 cites W2340636398 @default.
• W2561235181 cites W2407801906 @default.
• W2561235181 cites W2430551214 @default.
• W2561235181 cites W2467321712 @default.
• W2561235181 cites W2470779635 @default.
• W2561235181 cites W2481062620 @default.
• W2561235181 cites W2509481886 @default.
• W2561235181 cites W2513200835 @default.
• W2561235181 cites W2519986995 @default.
• W2561235181 cites W2520028087 @default.
• W2561235181 cites W2548020690 @default.
• W2561235181 cites W2560367415 @default.
• W2561235181 cites W2572174216 @default.
• W2561235181 cites W2597802455 @default.
• W2561235181 cites W2917837889 @default.
• W2561235181 doi "https://doi.org/10.18632/oncotarget.14069" @default.
• W2561235181 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5354736" @default.
• W2561235181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28030840" @default.
• W2561235181 hasPublicationYear "2016" @default.
• W2561235181 type Work @default.
• W2561235181 sameAs 2561235181 @default.
• W2561235181 citedByCount "32" @default.
• W2561235181 countsByYear W25612351812017 @default.
• W2561235181 countsByYear W25612351812018 @default.
• W2561235181 countsByYear W25612351812019 @default.
• W2561235181 countsByYear W25612351812020 @default.
• W2561235181 countsByYear W25612351812021 @default.
• W2561235181 countsByYear W25612351812022 @default.
• W2561235181 countsByYear W25612351812023 @default.
• W2561235181 crossrefType "journal-article" @default.
• W2561235181 hasAuthorship W2561235181A5000441787 @default.
• W2561235181 hasAuthorship W2561235181A5036246350 @default.
• W2561235181 hasAuthorship W2561235181A5047704890 @default.
• W2561235181 hasAuthorship W2561235181A5055723755 @default.
• W2561235181 hasAuthorship W2561235181A5079594267 @default.
• W2561235181 hasAuthorship W2561235181A5081109406 @default.
• W2561235181 hasAuthorship W2561235181A5088195735 @default.
• W2561235181 hasBestOaLocation W25612351811 @default.
• W2561235181 hasConcept C121608353 @default.
• W2561235181 hasConcept C126322002 @default.
• W2561235181 hasConcept C143998085 @default.
• W2561235181 hasConcept C2779013556 @default.
• W2561235181 hasConcept C2780210213 @default.
• W2561235181 hasConcept C2780849966 @default.
• W2561235181 hasConcept C2781018059 @default.
• W2561235181 hasConcept C29537977 @default.
• W2561235181 hasConcept C502942594 @default.
• W2561235181 hasConcept C71924100 @default.
• W2561235181 hasConceptScore W2561235181C121608353 @default.
• W2561235181 hasConceptScore W2561235181C126322002 @default.
• W2561235181 hasConceptScore W2561235181C143998085 @default.
• W2561235181 hasConceptScore W2561235181C2779013556 @default.
• W2561235181 hasConceptScore W2561235181C2780210213 @default.
• W2561235181 hasConceptScore W2561235181C2780849966 @default.
• W2561235181 hasConceptScore W2561235181C2781018059 @default.
• W2561235181 hasConceptScore W2561235181C29537977 @default.
• W2561235181 hasConceptScore W2561235181C502942594 @default.
• W2561235181 hasConceptScore W2561235181C71924100 @default.
• W2561235181 hasIssue "6" @default.
• W2561235181 hasLocation W25612351811 @default.
• W2561235181 hasLocation W25612351812 @default.
• W2561235181 hasLocation W25612351813 @default.
• W2561235181 hasLocation W25612351814 @default.
• W2561235181 hasOpenAccess W2561235181 @default.

• next